Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged VIIR

Check Out Prof. Sanjay Bakshi’s Latest Recommendation



Prof. Sanjay Bakshi is a staunch believer in the philosophy that you must not give a man fish but you must teach him how to fish so as to empower him for a lifetime

Is Prof. Sanjay Bakshi Justified In Letting His Morals Dictate Stock Market Decisions?



Prof. Sanjay Bakshi, the authority on value investing, lost out on a great investment opportunity owing to his belief that the stock’s business is a “moral hazard” and “bad for civilization“. Is he justified in mixing ethics with business?

Rahul Saraogi Of Atyant Capital Explains Why His “Deep Value” Stock Pick Is Still A Great Buy



Rahul Saraogi’s analysis of how and why he picked a stock which is/ was in the doldrums gives us an opportunity to understand how value investing works

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 493 other subscribers

RSS Stocks Talk Forum

  • Top Picks Basket of 16 Stocks (8 Large-Cap, 5 Mid-Cap & 3 Small-Cap)
    Top Picks Basket of 16 Stocks (8 Large-Cap, 5 Mid-Cap & 3 Small-Cap) for Nov '24. The Basket has delivered return of 329% since inception (May’20) vs 162% return delivered by NIFTY Index over the same period due to thematic approach to Top Picks selection Download report
  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!